Willie B. Thomas/DigitalVision via Getty Images I believe it is increasingly apparent that Concentra ( CON ) is becoming a dominant player within its segment of the healthcare industry and possesses a unique structural advantage that enables consistent growth. My bullish outlook is not based on speculation and rapid growth, but rather the proven ability of Concentra to implement a roll-up strategy...
Willie B. Thomas/DigitalVision via Getty Images I believe it is increasingly apparent that Concentra ( CON ) is becoming a dominant player within its segment of the healthcare industry and possesses a unique structural advantage that enables consistent growth. My bullish outlook is not based on speculation and rapid growth, but rather the proven ability of Concentra to implement a roll-up strategy in a significantly fragmented market while achieving economies of scale that are unattainable for smaller companies. Preliminary 2025 Financial Performance The unaudited preliminary financial statements show strong support for the company’s direction and execution as an operating business. Specifically, for the last quarter of 2025 Concentra had total revenues of $539.1 million. This amount is 15.9% greater than the $465.0 million in total revenues that were reported for the same quarter in 2024. What is especially impressive about this increase in total revenues is that it was not solely due to the addition of new clinics. In other words, Concentra’s underlying unit economics improved. In terms of patient visits for the last quarter of 2025, Concentra had just under 3.3 million patients come into their clinics. As a result, the average number of patients visiting each of the company’s clinics per day is now 51,005. In comparison to the previous year’s average number of patients visiting each clinic per day, which was 46,797, this is a 9.0% increase. Concentra has also seen a 3.1% increase in revenue per patient visit, resulting in an average revenue per visit of $149.63. The combination of increasing both the number of patients visiting each clinic, as well as the revenue per patient visit, clearly demonstrate the company’s ability to grow prices as they grow volumes. In the statement, we also see that the benefit of increasing the size of the company (operating leverage), while keeping costs constant, is evidenced in several ways. For the fourth quarter of 2025, Concentr...